You are here: Industry Insights > Avigan

News List

Appili to progress Phase III oral Covid-19 treatment trial pharmaceutical-technology
May 18, 2021
Appili Therapeutics is set to continue its ongoing Phase III PRESECO trial of oral therapy, Avigan/Reeqonus (favipiravir), without modification to treat mild-to-moderate Covid-19.
Dr. Reddy's and GRA Announce Clinically Meaningful Data from Avigan Pivotal Studies prnasia
January 28, 2021
Dr. Reddy's Laboratories Ltd. and Global Response Aid FZCO (GRA) today announced results from an Avigan study on moderate-severe hospitalized COVID-19 patients in Kuwait.
Appili announces dosing of first patient in phase 3 Covid-19 trial pharmaceutical-business-review
December 07, 2020
Appili Therapeutics announced that first patient has been dosed in the phase 3 PRESECO (preventing severe Covid disease) clinical trial to assess oral Avigan tablets (favipiravir) to treat Covid-19.
Health Canada clears Appili Therapeutics for new phase 3 trial to assess Avigan to prevent Covid-19 pharmaceutical-business-review
November 27, 2020
Appili Therapeutics, a biopharmaceutical company focused on anti-infective drug development, announced initiation of its Phase 3 Post Exposure Prophylaxis for COVID-19 (PEPCO) study to evaluate Avigan tablets (favipiravir) in the prevention of Covid-19.
Avigan Shows Promising Results in Treatment of COVID Patients in Japan americanpharmaceuticalreview
September 30, 2020
Global Response Aid (GRA) and Dr. Reddy's Laboratories announced the anti-viral drug Avigan® produced promising results in a single-blinded, placebo-controlled Phase 3 clinical study conducted in Japan with the sponsorship of FujiFilm Toyama Chemical.
Fujifilm to seek approval for Avigan in Covid-19 after positive data pharmaceutical-technology
September 27, 2020
Japan’s Fujifilm Toyama Chemical plans to seek approval for its anti-viral drug Avigan (favipiravir) to treat patients with Covid-19, after obtaining positive results in Phase III clinical trial.
Dr Reddy’s Laboratories launches AVIGAN (favipiravir) in India expresspharma
August 20, 2020
Dr Reddy’s Laboratories announced the launch of AVIGAN (favipiravir) 200 mg tablets in India.
Dr Reddy’s signs agreement with FUJIFILM and Global Response Aid for Avigan (favipiravir) expresspharma
July 02, 2020
Dr Reddy’s would have exclusive rights for development, selling and distribution of Avigan in India.
Fujifilm shares fall after report Avigan not showing clear efficacy in some coronavirus trials expresspharma
May 21, 2020
The data reported to Japan’s health ministry by hospitals treating people showing mild or no symptoms raises doubts about whether the drug can be approved by the end of this month.
Doubt cast over Avigan (favipiravir) and DAS181 potential to fight COVID-19 europeanpharmaceuticalreview
May 15, 2020
A new report has highlighted that the early successes of Avigan (favipiravir) and DAS181 do not guarantee their efficacy against COVID-19.

Previous page 1 2 Next page